Health Startup Noom Adding GLP-1 Drugs to Med Plan Now
Noom is shifting from psychology-based weight loss to prescription treatments, launching Noom Med in a multi-state ro...
This intro examines risk profiles for index vs target date funds, offering a clear take on volatility, diversification, and potential drawdowns.
24,893 articlesNoom is shifting from psychology-based weight loss to prescription treatments, launching Noom Med in a multi-state ro...
Bank of America projects a future where humanoid robots outnumber cars by 2060, with two-thirds living in households....
Robot dogs priced $300,000 are stepping into data-center security as AI investment surges. The four-legged guards pro...
Mosaic’s rare earths could become a new growth engine as the company partners with Rainbow Rare Earths to recover NdP...
Lululemon has faced headwinds after a peak stretch. This article outlines whether lululemon stock recover? is feasibl...
An insurer’s blockbuster profit alongside an insider stock sale creates a compelling investing puzzle. This article b...
Planet Labs delivered its first full year of profitability, with a ballooning backlog and AI partnerships driving a r...
Remitly’s 2026 earnings outlook hinges on user growth, cross-border volumes, and unit economics. This guide breaks do...
This article breaks down United Parks PRKS 2026 Q1 earnings, highlighting revenue growth, margins, and the drivers sh...
Three under-$10 energy names are drawing attention as one yields 8.8%, another is up 83% in a year, and market chatte...
Boot Barn stands at a crossroads in 2026. This guide breaks down the growth drivers, potential risks, and practical i...
Stocks edge higher as Nvidia earnings loom, lifting the S&P 500 and Nasdaq. This stock market live 2026 update tracks...